Study of Spinraza in pregnancy for 5q spinal muscular atrophy
Part of Brain & nervous system clinical trials.
This study looks at how Spinraza (nusinersen) taken during or before pregnancy affects people with 5q spinal muscular atrophy (SMA) and the health of their babies. It mainly fits those who were pregnant and received Spinraza around the time of conception or during pregnancy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are (or were) pregnant during the study’s exposure window, including during pregnancy.
- You are in one of these registries: US ISMAR, UK Adult SMA REACH, or the SMArtCARE network (Germany/Austria/Switzerland).
- Your SMA diagnosis is confirmed by genetics as “5q SMA” (linked to chromosome 5q).
- You received Spinraza (nusinersen) up to about 14–14.5 months before conception and/or during pregnancy.
- You did not take risdiplam (also an SMA medicine) from about 2 weeks before conception through pregnancy, and you do not plan to take it during pregnancy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the drug salanersen can help movement and is safe when given to babies diagnosed with spinal muscular atrophy before they show symptoms. It's for very young infants with specific genetic types of SMA.
This trial investigates how the drug nusinersen (Spinraza) enters the body when given through a small, flexible tube placed in the lower back (ThecaFlex DRx system). It aims to learn how the drug is processed in adults and children with spinal muscular atrophy, which could help make dosing more convenient.
This trial studies whether risdiplam, given early after gene therapy, is safe and helps children with spinal muscular atrophy (SMA) keep improving or stay stable. It focuses on children under 2 years old who already received gene therapy and need to meet timing and health requirements.
This trial studies whether risdiplam is safe and helpful for children under 2 with spinal muscular atrophy (SMA) whose function has leveled off or declined after gene therapy. It may be an option if you saw benefits from gene therapy but then noticed a stop or setback in key abilities.
This study creates a registry and clinical hub for adults with 5q spinal muscular atrophy (SMA). It aims to track health outcomes and improve care for people living with SMA.
This study is looking for children and teens with spinal muscular atrophy (SMA) who are already on a treatment like Spinraza, Evrysdi, or Zolgensma. The goal is to understand different forms of SMA and how the treatment affects them over time.
Hear when a new Muscular Atrophy, Spinal trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.